ADBE, LULU, TGT, IQV, SPGI: Open Picks Review June 2026

Six months into 2026, the open picks portfolio spans a wide range of setups: a battered software compounder, a turnaround retailer, a CRO trading at a steep discount to peers, a Dividend King with an activist at the table, and a financial-data giant sitting on a spin catalyst. Here is where each one stands as of June 18, 2026, using the latest data.

Adobe (ADBE): The Market Is Pricing in Permanent Decline

Adobe is the most polarizing name on the list. The stock is down 47.1% over the past year, which is a brutal drawdown for a business posting 12.7% revenue growth, 28.7% net margins, and 62.9% ROE. The FCF yield sits at 12.0%, a figure more commonly associated with mature industrials than a software company growing AI annual recurring revenue past $500M.

The forward P/E of 8.5x is the number that stops most analysts cold. That multiple implies the market believes Adobe's earnings power is either about to collapse or that AI tools will commoditize its creative suite within a few years. Neither scenario is obviously correct. The quality score of 96/100 reflects a balance sheet with net cash and margins that have held through the AI disruption narrative. The momentum score of 17/100 reflects the reality that the stock has no near-term buyers.

The CFO departure that triggered the initial selloff has not been followed by any operational deterioration visible in the numbers. Analyst consensus sits at $288.48. The thesis here is patience: the business is compounding, the price is not.

lululemon (LULU): Cheap on Quality, Expensive on Growth

lululemon trades at 10.2x forward earnings with 57%-range gross margins, zero debt, 32% ROE, and 7.0% FCF yield. The quality score of 85/100 confirms this is not a broken business.

The problem is the growth score of 28/100. Revenue grew just 4.3% year over year, and earnings fell 35.0%. For a brand that once commanded 30x-plus multiples on the promise of durable double-digit growth, that deceleration is the entire bear case. Two activists and a board vote on June 25 add a near-term catalyst, but activists rarely fix a demand problem quickly.

The value score of 87/100 says the stock is cheap relative to its own history and quality metrics. The analyst target of $135.74 implies meaningful upside from current levels. The pick thesis rests on the brand's pricing power and international expansion holding up while management changes take effect. The June 25 board vote is the first real signal.

Target (TGT): The Turnaround Has Numbers Behind It

Target is the cleanest near-term story in the portfolio. The company posted its first post-earnings guidance raise in two years, confirming that CEO Brian Cornell's successor Jim Fiddelke is executing. The stock trades at 16.3x forward earnings with a 3.4% dividend yield and 4.7% FCF yield.

The momentum score of 97/100 stands out. Target is up 36.7% over the past year, the strongest price performance in this group. Revenue grew 6.7% year over year. The value score of 79/100 says the stock is not expensive for a retailer with this quality profile.

The bear case is simple: net margin is 3.2%, which leaves little room for error if consumer spending softens. But the guidance raise suggests management has visibility into the back half of the year. The analyst target of $131.81 reflects a market that has not fully repriced the turnaround.

IQVIA (IQV): The Discount Is Real, the Catalyst Is Unclear

IQVIA Holdings is the largest pure-play contract research organization and healthcare data business in the world, and it trades at 13.9x forward earnings. Revenue grew 8.4% year over year, earnings grew 15.0%, and the FCF yield is 6.8%. ROE of 22.5% is solid for a capital-intensive services business.

The value score of 71/100 and quality score of 59/100 together describe a business that is genuinely cheap relative to peers but not without operational complexity. The growth score of 60/100 reflects steady rather than accelerating demand. The momentum score of 45/100 tells you the market has not yet arrived at the same conclusion.

The analyst target of $226.95 implies the discount is roughly a third below consensus. The missing piece is a catalyst. Clinical trial activity, pharma R&D budgets, and FDA approval timelines all feed into IQV's revenue. Any acceleration in drug approvals or a pickup in biotech funding would move this name quickly.

S&P Global (SPGI): Down 17% YTD, Spin Catalyst Dated July 1

S&P Global is down 15.8% over the past year, which is a meaningful underperformance for a business with 30.4% net margins, 86/100 quality score, and 32.5% earnings growth year over year. Revenue grew 10.4%. The forward P/E of 22.1x is not cheap in absolute terms, but it is well below the historical range for a business with this margin and growth profile.

The July 1 spin catalyst is the near-term event. The market has priced the stock roughly 25% below analyst consensus of $533.76. The growth score of 76/100 reflects the underlying momentum in ratings, data, and analytics revenue. The momentum score of 31/100 reflects the YTD drawdown.

S&P Global is a Dividend King with a 0.9% yield, which is not the reason to own it. The reason is that a business compounding earnings at this rate rarely stays this far below consensus for long.

The Common Thread

Five of these picks share a structure: quality metrics that are intact, valuations that are compressed relative to history, and a specific catalyst or activist dynamic that could close the gap. None of them are momentum trades. ADBE (ACCE score 64/100), LULU (54/100), TGT (65/100), IQV (59/100), and SPGI (61/100) all sit in a mid-range band that reflects the tension between strong fundamentals and weak near-term price action.

The next 60 days bring two hard dates: the LULU board vote on June 25 and the SPGI spin on July 1. PepsiCo (PEP) earnings in mid-July will also test whether the Elliott-driven cost narrative has legs. These events will either validate the thesis on each name or force a reassessment.

The picks that have the most to prove are ADBE and LULU. The one with the clearest near-term evidence is TGT. IQV and SPGI sit somewhere in between, waiting for a catalyst that is either structural or event-driven to surface.